A Multiplex Microsphere IgG Assay for SARS-CoV-2 Using ACE2-Mediated Inhibition as a Surrogate for Neutralization
Andrew Cameron, Claire A. Porterfield, Larry D. Byron, Jiong Wang, Zachary Pearson, Jessica L. Bohrhunter, Anthony B. Cardillo, Lindsay Ryan-Muntz, Ryan A. Sorensen, Mary T. Caserta, Stephen V. Angeloni, Dwight J. Hardy, Martin S. Zand, Nicole Pecora
Abstract
= 140) whose COVID-19 course was characterized through chart review. This revealed the relative rise, peak (S, 23.8; RBD, 23.6; NP, 16.7 [in days from symptom onset]), and decline of the antibody response. Considerable interperson variation was observed with a subset of extensively sampled intensive care unit (ICU) patients. Using soluble ACE2, inhibition of antibody binding was demonstrated for S and RBD, and not for NP. Taking the data together, this study described the performance of an assay built on a flexible and high-throughput serological platform that proved adaptable to the emergence of a novel infectious agent.